Eligibility Module

Eligibility Module

The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.

Eligibility Module path is as follows:

Study -> Protocol Section -> Eligibility Module

Eligibility Module


Ignite Creation Date: 2025-12-24 @ 1:17 PM
Ignite Modification Date: 2025-12-24 @ 1:17 PM
NCT ID: NCT00214695
Eligibility Criteria: Inclusion Criteria: * Patients who have given written informed consent after the nature of the study has been explained. * Patients who are at least 18 years of age. * Patients who have been treated with PD using specific solutions for at least 30 days before the screening visit. * Patients who experience pain on infusion based on medical judgement. Exclusion Criteria: * Patients who have received antibiotics for the treatment of an episode of peritonitis within 30 days before to screening visit. * Patients who have had acute or chronic exit-site or tunnel infection in the past 14 days, counted from the last day of infection to the screening visit. * Patients who are participating in another study that requires Ethics Committee approval. Non-interventional studies are permitted. * Patients who have received an investigational product within 30 days preceding the screening visit. * Patients who are pregnant or lactating. (NB: Female patients of childbearing potential must have a negative urine or serum pregnancy test at the time of the screening and will be required to use a medically acceptable means of contraception during their participation in this study). * Patients who have a significant psychiatric disorder or mental disability that could interfere with his/her ability to provide informed consent and/or comply with protocol procedures.
Healthy Volunteers: False
Sex: ALL
Minimum Age: 18 Years
Study: NCT00214695
Study Brief:
Protocol Section: NCT00214695